London, UK, 19 June 2001- ReminylTM (galantamine), a new treatment for mild to moderate Alzheimer's disease derived from the daffodil, is the first medication of its kind shown to be potentially effective in treating dementia in patients with cerebrovascular disease, such as stroke.
Data from a study presented here today at the XVII World Congress of Neurology show that Reminyl improves memory, orientation and language skills of patients with vascular dementia or a combination of Alzheimer's disease and cerebrovascular disease ("mixed" dementia) for at least 12 months. The results also showed that Reminyl improved or maintained the ability of these individuals to perform normal activities of daily living, such as bathing, dressing and doing housework. However, Reminyl is not yet approved for the treatment vascular dementia.
"This study has the potential to make a real impact on the way dementia is treated throughout the world," says Dr Roger Bullock of the Kingshill Research Centre in Swindon, UK. "If the findings of this study are replicated through further research, physicians will no longer need to hesitate before treating dementia in individuals in whom vascular damage has occurred. Reminyl appears to be effective in treating dementia, whether or not cerebrovascular disease is present."
Dementia is a decline in memory and intellectual abilities that results in a significantly impaired ability to function.1 The most common type of dementia is Alzheimer's disease. However, the second most common type is vascular dementia, which often is triggered by one or more strokes and can be caused by uncontrolled hypertension or diabetes.
World-wide incidence of vascular dementia is estimated at six to 12 cases per 1,000 people more than 70 years of age.2 Many other individuals have a mix of Alzheimer's and cerebrovascular disease. In fact, it is estimated that between 10 and 50 per cent of individuals have either vascular or mixed dementia. Unf
Contact: Roseann Ward